Article Text

See original article:

Download PDFPDF
p53 gene (Gendicine) and embolisation overcame recurrent hepatocellular carcinoma
  1. Y S Guan,
  2. Y Liu,
  3. X P Zhou,
  4. X Li,
  5. Q He,
  6. L Sun
  1. Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuang Province, China
  1. Correspondence to:
    Professor Y-S Guan
    Department of Radiology, West China Hospital, Sichuan University, 37 Guoxuexiang, Chengdu 610041, Sichuan Province, China;


Transcatheter arterial chemoembolisation (TACE) has become the standard treatment for unresectable hepatocellular carcinoma (HCC). However, this method is often unsuccessful. The p53 gene, which is present as a mutant form in many human tumours, is known to have broad spectrum antitumour effects when expressed normally. In this study, we report a 23 year old patient with recurrent HCC who was treated with the p53 gene (Gendicine) combining TACE, which resulted in a good clinical prognosis.

  • TACE, transcatheter arterial chemoembolisation
  • HCC, hepatocellular carcinoma
  • CT, computed tomography
  • VP, virus particles
  • hepatocellular carcinoma
  • p53 gene
  • transcatheter arterial chemoembolisation

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Conflict of interest: None declared.

Linked Articles

  • Robin Spiller
  • Notice of withdrawal
    BMJ Publishing Group Ltd and British Society of Gastroenterology